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Functional characterisation of decoy receptor 3 in Crohn's
disease
Abstract
AIMS: Both epithelial barrier dysfunction and apoptosis resistance of immune cells contribute to the
pathogenesis of Crohn's disease. The soluble decoy receptor 3 (DcR3) acts in an anti-apoptotic manner
by neutralising the death ligand CD95L. Here, we investigated the possible involvement of DcR3 in
Crohn's disease. METHODS: The epithelial fraction of human small intestinal mucosa samples was
obtained by laser microdissection. Expression of DcR3 was examined by global gene expression
profiling, quantitative reverse transcription polymerase chain reaction, immunoblot analysis, and
immunohistochemistry. DcR3 concentrations in the serum of patients with Crohn's disease were
measured by enzyme-linked immunosorbent assay. Apoptosis assays were performed to study the
effects of DcR3 in intestinal epithelial cells and lamina propria T cells. RESULTS: DcR3 is
over-expressed in the epithelial layer of ileum specimens in patients with Crohn's disease, both at
actively inflamed and non-active sites. DcR3 serum levels are significantly elevated in patients with
active and non-active Crohn's disease as compared to healthy controls. The expression of DcR3 in
intestinal epithelial cells is induced by tumour necrosis factor alpha. Increased DcR3 expression is
associated with activation of nuclear factor kappa B (NF-kappaB) and results in protection of intestinal
epithelial cells and lamina propria T cells from CD95L-induced apoptosis. CONCLUSIONS: DcR3 may
promote inflammation in Crohn's disease by inhibiting CD95L-induced apoptosis of epithelial and
immune cells as well as by inducing NF-kappaB activation.
doi: 10.1136/gut.2008.148908
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ABSTRACT
Aims: Both epithelial barrier dysfunction and apoptosis
resistance of immune cells contribute to the pathogenesis
of Crohn’s disease. The soluble decoy receptor 3 (DcR3)
acts in an anti-apoptotic manner by neutralising the death
ligand CD95L. Here, we investigated the possible
involvement of DcR3 in Crohn’s disease.
Methods: The epithelial fraction of human small intestinal
mucosa samples was obtained by laser microdissection.
Expression of DcR3 was examined by global gene
expression profiling, quantitative reverse transcription
polymerase chain reaction, immunoblot analysis, and
immunohistochemistry. DcR3 concentrations in the serum
of patients with Crohn’s disease were measured by
enzyme-linked immunosorbent assay. Apoptosis assays
were performed to study the effects of DcR3 in intestinal
epithelial cells and lamina propria T cells.
Results: DcR3 is over-expressed in the epithelial layer of
ileum specimens in patients with Crohn’s disease, both at
actively inflamed and non-active sites. DcR3 serum levels
are significantly elevated in patients with active and non-
active Crohn’s disease as compared to healthy controls.
The expression of DcR3 in intestinal epithelial cells is
induced by tumour necrosis factor a. Increased DcR3
expression is associated with activation of nuclear factor
kappa B (NF-kB) and results in protection of intestinal
epithelial cells and lamina propria T cells from CD95L-
induced apoptosis.
Conclusions: DcR3 may promote inflammation in Crohn’s
disease by inhibiting CD95L-induced apoptosis of epithelial
and immune cells as well as by inducing NF-kB activation.
The mucosal inflammation in chronic inflammatory
bowel disease (IBD) is promoted by epithelial barrier
defects, inappropriate innate immune responses, and
dysregulations in the adaptive immune system.
Resistance of T cells against the induction of
apoptotic cell death has been identified as one factor
which promotes local T cell accumulation and
further perpetuates the chronic mucosal inflamma-
tion.1 Physiologically, T lymphocytes are at least
partially eliminated via death receptor-dependent
mechanisms in response to stimulation by environ-
mental antigens. Apoptotic death of T cells is
accomplished upon binding of the death ligand
CD95L to its receptor CD95 or, alternatively, upon
binding of the death ligand TRAIL to one of its pro-
apoptotic receptors, TRAIL-R1 or TRAIL-R2. The so-
called decoy receptors are proteins that belong to the
tumour necrosis factor receptor superfamily and
inhibit death ligand-induced apoptosis by binding to
and neutralising the death ligands TRAIL and
CD95L. Whereas decoy receptors 1 and 2 (DcR1,
DcR2) bind to TRAIL, the soluble decoy receptor 3
(DcR3, also known as TR6, M68) interacts with
CD95L, LIGHT and TNF-like molecule 1A (TL1A).2–5
Some experimental data indicate that over-expres-
sion of DcR1, DcR2 and DcR3 might contribute to a
diminished induction of apoptosis in T cells from
inflamed mucosa in ulcerative colitis.6
An altered expression and function of cell–cell
adhesion proteins such as the intercellular cell
adhesion molecule-1 (ICAM-1) might contribute to
the development of an epithelial barrier dysfunc-
tion in IBD. These proteins are involved in
leukocyte trafficking to endothelial and epithelial
sites, but can also facilitate pathogen invasion,
possibly caused by an increased adherence of
bacteria to the luminal surface of the intestinal
epithelium.7 The role of defects in the regulation of
apoptosis in enterocytes for the epithelial barrier
dysfunction in IBD is less clear. However, apopto-
sis resistance of enterocytes is considered to be of
relevance for the process of IBD-associated carci-
nogenesis, where a deregulated activation of
nuclear factor kappa B (NF-kB)-dependent pro-
survival signalling pathways may contribute to the
malignant transformation of enterocytes.
To further dissect molecular changes within the
epithelial compartment of the gut mucosa in
Crohn’s disease, we performed a global gene
expression analysis of microdissected epithelial
fractions of human intestinal tissue. We identified
DcR3 as a gene that is over-expressed in the
intestinal epithelium in Crohn’s disease and we
functionally characterised the role of DcR3 in
epithelial intestinal cells. Our findings suggest that
upregulation of DcR3 is involved in apoptosis
resistance, promotion of inflammation in Crohn’s
disease, and possibly also carcinogenesis.
PATIENTS AND METHODS
Patients (tissue and sera)
Resection specimens were obtained from the
Department of Surgery, University Hospital
Heidelberg. Informed consent was obtained from
the patients. Diagnosis was established according to
clinical and conventional histopathological criteria.
Clinical features of the patients are provided in
tables 1 and 2, and in the supplement (parts 1 and 2).
For a detailed description of how the inflammatory
status (active vs noninflamed/inactive) of the
Crohn’s disease samples was determined by histo-
pathology, see the supplement (part 3).
Laser microdissection and pressure catapulting
Fresh frozen small intestinal mucosa samples were
cut into 18 mm thick sections using a cryostat
Inflammatory bowel disease
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(Leica CM1850; Leica Microsystems, Wetzlar, Germany) and
processed as described in the supplement (part 4).
Isolation of RNA in microdissected samples
Total RNA was isolated from each sample using the Chomczynski/
Sacchi method8 according to the manufacturer’s instructions
(peqGOLD TriFast kit; PeqLab Biotechnologie, Erlangen
Germany). For precipitation 2 ml of Pellet Paint Co-Precipitant
(Novagen, San Diego, California, USA) per sample were used.
Subsequently, isolated RNA was purified using an Absolutely RNA
Nanoprep Kit (Stratagene, La Jolla, California, USA). The quality of
the RNA was assessed on RNA 6000 Nano microfluidics chips
(Agilent Technologies, Waldbronn, Germany) on an Agilent 2100
BioAnalyzer according to the manufacturer’s instructions.
High-density oligonucleotide microarray analysis
All experiments were performed using Affymetrix HG-U133 Plus
2.0 GeneChips oligonucleotide arrays (Affymetrix, High
Wycombe, UK), as described at http://www.affymetrix.com/
products/arrays/specific/hgu133plus.affx (accessed 16 December
2008). Hybridisation, data collection, and data processing were
performed as outlined in the supplement (part 5).
Quantitative real-time polymerase chain reaction
RNA samples (100 ng total RNA) were reverse-transcribed into
cDNA by REVERSE-IT max 1st strand synthesis kit according to
the manufacturer’s protocol (Abgene, Hamburg, Germany).
Real-time monitoring of PCR reactions was performed as
described in the supplement (part 6).
Table 1 Summary of clinical features: gene chip and quantitative polymerase chain reaction analysis
Experiment Group Sex
Age
(years) Diagnosis
Disease duration
(years) Surgery Medication
Gene chip Control M 77 Adenocarcinoma of the
colon
– Right hemicolectomy –
F 73 Tubulovillous adenoma of
the colon
– Ileocaecal resection –
M 76 Pancreatic cancer – Pancreatic/small bowel
resection
–
Active/non-active Crohn’s
disease
M 29 Crohn’s disease 16 Ileal resection No anti-inflammatory
drugs
F 32 Crohn’s disease 2 Ileocaecal resection No anti-inflammatory
drugs
M 45 Crohn’s disease 24 Ileocolonic resection No anti-inflammatory
drugs
Quantitative polymerase
chain reaction
Control M 77 Adenocarcinoma of the
colon
– Right hemicolectomy –
F 73 Villous adenoma of the
colon
– Ileocaecal resection –
M 64 Malignant fibrous
histiocytoma
– Ileal resection –
M 57 Tubulovillous adenoma of
the colon
– Right hemicolectomy –
M 76 Adenocarcinoma of the
colon
– Right hemicolectomy –
M 76 Pancreatic cancer – Pancreatic/small bowel
resection
–
M 70 Adenocarcinoma of the
caecum
– Right hemicolectomy –
F 58 Adenocarcinoma of the
colon
– Right hemicolectomy –
Active Crohn’s disease M 29 Crohn’s disease 16 Ileal resection No anti-inflammatory
drugs
M 26 Crohn’s disease NA Ileal resection NA
M 46 Crohn’s disease NA Ileal resection NA
F 45 Crohn’s disease NA Ileal resection NA
F 34 Crohn’s disease 1 Ileocaecal resection 5-ASA
F 41 Crohn’s disease NA Ileocaecal resection NA
M 31 Crohn’s disease 8 Ileal resection No anti-inflammatory
drugs
M 33 Crohn’s disease NA Ileal resection NA
Non-active Crohn’s
disease
M 45 Crohn’s disease 24 Ileocolonic resection No anti-inflammatory
drugs
F 45 Crohn’s disease 19 Ileocolonic resection 5-ASA
M 29 Crohn’s disease 16 Ileal resection No anti-inflammatory
drugs
F 32 Crohn’s disease 2 Ileocaecal resection No anti-inflammatory
drugs
M 30 Crohn’s disease NA Ileocaecal resection NA
M 46 Crohn’s disease NA Ileocolonic resection NA
F 18 Crohn’s disease 1 Ileocaecal resection 5-ASA
M 33 Crohn’s disease NA Ileal resection NA
F 38 Crohn’s disease 22 Ileocaecal resection NA
5-ASA, 5-aminosalicylic acid; F, female; M, male; NA, not applicable.
Inflammatory bowel disease
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Immunohistochemistry
Tissue sections of non-inflamed (n = 7) and inflamed (active
Crohn’s disease, n = 6; non-active Crohn’s disease, n = 4) small
intestine were analysed for DcR3 and ICAM-1 expression by
immunohistochemistry. The immunohistochemical staining
procedure is outlined in the supplement (part 7).
Enzyme-linked immunosorbent assay of decoy receptor 3
Serum DcR3 levels were measured by the human DcR3-specific
quantitative ELISA as described previously.9 For a brief outline
of the procedure, see the supplement (part 8).
Cell lines
SW480 and HCT116 adherent intestinal epithelial cell lines
derived from colon adenocarcinomas were maintained in RPMI
1640 (Invitrogen, Karlsruhe, Germany) containing 10% fetal calf
serum (FCS), and 1% penicillin–streptomycin (Invitrogen) at
37uC and 5% CO2.
Transfections
Stable ectopic expression of DcR3 in SW480 cells was obtained
by co-transfecting the cells with the pRK5-DcR3 plasmid2 and
the pcDNA3 neo control plasmid by the lipofectamine method
(Lipofectamin 2000; Invitrogen). The cells were selected with
G418 (750 mg/ml), starting 48 h after transfection. As controls,
stable transfectants were generated with the empty pcDNA3
expression vector. Expression of the transgene was confirmed by
immunoblot analysis and PCR.
Immunoblot analysis
Immunoblot analysis was performed as outlined in the
supplement (part 9).
Cytotoxicity
HCT116 cells were plated into 96-well plates (20 000 cells/well)
and after 24 h treated with leucine zipper-tagged CD95 ligand
(LZ-CD95L)-containing supernatants (kindly provided by PH
Krammer, Heidelberg), TRAIL (Biomol), human recombinant
DcR3 (rhDcR3/Fc chimera, R&D Systems, Wiesbaden,
Germany), and/or DcR3-containing supernatants derived from
SW480 cells stably transfected with a plasmid encoding human
DcR3 cDNA.2 After 24 h cell survival was measured by crystal
violet staining as described previously.10
Preparation of T cells from intestinal lamina propria and killing
assays
Normal mucosa was dissected from freshly resected gut from
patients undergoing partial colectomy for non-IBD-related loca-
lised colon cancer. The preparation of lamina propria T cells and
the killing assays are described in the supplement (part 10).
Statistical analysis
Data was analysed as outlined in the supplement (part 11).
Table 2 Summary of clinical features: immunohistochemical analysis of decoy receptor 3 (DcR3) expression
Group Sex Age (years) Diagnosis Disease duration (years) Surgery/biopsy Medication
Control F 75 Adenocarcinoma of the caecum – Right hemicolectomy –
F 86 Adenocarcinoma of the caecum – Right hemicolectomy –
F 81 Adenocarcinoma of the colon – Right hemicolectomy –
M 87 Adenocarcinoma of the colon – Right hemicolectomy –
F 83 Adenocarcinoma of the caecum – Right hemicolectomy –
F 86 Adenocarcinoma of the caecum – Right hemicolectomy –
F 60 Adenocarcinoma of the caecum – Right hemicolectomy –
M 45 – – Biopsy –
F 22 – – Biopsy –
M 16 – – Biopsy –
F 39 – – Biopsy –
M 39 – – Biopsy –
M 24 – – Biopsy –
F 43 – – Biopsy –
F 24 – – Biopsy –
F 37 – – Biopsy –
F 23 – – Biopsy –
F 30 – – Biopsy –
F 28 – – Biopsy –
M 43 – – Biopsy –
M 40 – – Biopsy –
M 44 – – Biopsy –
Active Crohn’s disease F 44 Crohn’s disease 2 Ileal resection NA
F 40 Crohn’s disease NA Ileal resection NA
F 31 Crohn’s disease 5 Ileocaecal resection No anti-inflammatory drugs
F 55 Crohn’s disease NA Ileal resection 10 mg prednisone/day
M 42 Crohn’s disease 16 Ileal resection NA
M 40 Crohn’s disease NA Ileocaecal resection NA
Non-active Crohn’s disease F 36 Crohn’s disease NA Ileal resection NA
M 42 Crohn’s disease 16 Ileal resection NA
F 44 Crohn’s disease 2 Ileal resection NA
F 31 Crohn’s disease 5 Ileocaecal resection No anti-inflammatory drugs
F, female; M, male; NA, not applicable.
Inflammatory bowel disease
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RESULTS
Decoy receptor 3 is upregulated in the small intestinal epithelium
in Crohn’s disease
Several global gene expression studies have been performed to
identify genes that are relevant for the development and
progression of IBDs.11–15 However, the use of total mucosal
tissue for such studies does not allow the expression of certain
genes to be allocated to a defined tissue compartment within
the bowel wall, such as epithelium or lamina propria. To
identify genes that are specifically regulated in the epithelial
layer of the small intestine in patients with Crohn’s disease, we
performed MicroImaging-based laser microdissection of freshly
obtained small-intestinal tissue samples from actively inflamed
as well as non-active areas of specimens with Crohn’s disease or
non-inflammatory bowel diseases (normal controls). The
clinical features of the patients are summarised in table 1 and
in the supplement (part 1). One of the genes that was most
prominently upregulated in Crohn’s disease as compared to
controls was the soluble CD95L-neutralising DcR3 (fig 1A).
Interleukin 8, a cytokine that is classically induced by
inflammatory conditions, was upregulated to a similar extent
as DcR3 in samples with active Crohn’s disease, but not in non-
active Crohn’s disease. Interestingly, the pro-apoptotic death
ligand CD95L was moderately downregulated in Crohn’s
disease, as was the NF-kB-regulating gene IkBa. A strong
downregulation was also observed for TNF-like molecule 1A
(TL1A) which is an alternative binding partner of DcR3.
To confirm the findings of the Affymetrix gene chip analysis
in an independent and larger cohort of samples (table 1), we
analysed the expression of DcR3 mRNA in microdissected ileal
epithelium by quantitative RT-PCR analysis. DcR3 expression
was approximatly 22-fold upregulated in active Crohn’s disease
as compared to controls (fig 1B). The expression of DcR3 in
non-active Crohn’s disease was moderately, but still signifi-
cantly, increased when compared to normal control tissues.
Moreover, TL1A downregulation was confirmed by quantita-
tive RT-PCR analysis (see the supplement, part 12).
Since mRNA expression levels do not necessarily correspond
to protein expression levels, we performed immunoblot analyses
using lysates from mucosal tissue specimens of Crohn’s disease
and controls. In accordance with our finding of elevated DcR3
mRNA levels, the protein expression of DcR3 was strongly
upregulated in samples with active Crohn’s disease and
moderately upregulated in samples with non-active Crohn’s
disease (fig 1C). DcR3 protein expression in normal control ileal
mucosa was very weak or absent.
Over-expression of decoy receptor 3 occurs in ulcerative
epithelial lesions and in the follicle-associated epithelium
To characterise the localisation of upregulated DcR3 in more
detail, we performed immunohistochemical analysis of DcR3
expression in Crohn’s disease tissues and controls. The patients
and clinical features are summarised in table 2 and the
supplement (part 1). Ileal mucosa of normal controls displayed
only weak immunoreactivity for DcR3 which was confined to a
few scattered lamina propria mononuclear cells and some
surface epithelial cells at sites of mucosal lymphoid follicles
(fig 2A,B). Such structures represent a possible site of initial
inflammation in IBD.16 Enhanced immunostaining of such
follicle-associated epithelial (FAE) cells for DcR3 was apparent
in Crohn’s disease tissues, both in samples with non-active
(fig 2C,D) and active (fig 2E,F) disease. In actively inflamed
samples, epithelial expression of DcR3 in Crohn’s disease was
more widespread and included mucosal areas apart from
lymphoid follicles, especially in the vicinity of erosions and
ulcers (fig 2G–J). Subsets of mononuclear cells as well as
endothelia at ulcerative sites (fig 2K,L) also displayed positive
DcR3 immunoreactivity.
Increased serum levels of decoy receptor 3 in patients with
Crohn’s disease
Since DcR3 is a soluble protein, we next investigated whether
patients suffering from Crohn’s disease exhibit increased blood
serum concentrations of DcR3 protein. Serum samples from 56
patients with active or non-active Crohn’s disease and from 27
healthy control individuals were subjected to ELISA (for clinical
details, see the supplement, parts 1 and 2). Irrespective of the
presence of active or non-active disease, the DcR3 serum
concentrations of patients with Crohn’s disease were signifi-
cantly higher than in the control group (fig 3). DcR3 levels were
not significantly different between active and non-active
Crohn’s disease.
Tumour necrosis factor a upregulates the expression of decoy
receptor 3
Tumour necrosis factor a (TNFa) and interleukins (ILs) are
associated with early mucosal changes in IBD, such as epithelial
barrier dysfunction and increased local influx of leukocytes.17–19
Therefore, we investigated the impact of TNFa and IL1b on the
expression of DcR3 in the colonic epithelial cell line HCT116. A
24 h treatment with TNFa resulted in a 4.5-fold upregulation of
DcR3 mRNA (fig 4A). The incubation with IL1b resulted in a
smaller and short-lasting increase in DcR3 mRNA expression.
Induction of IL8 by TNFa and IL1b was used as a positive
control (fig 4B).
Decoy receptor 3 protects epithelial cells from CD95L-induced
cell death
To investigate the effects of increased DcR3 expression in
intestinal epithelial cells, we generated sublines of SW480 cells
that were stably transfected with a DcR3 expression plasmid. In
contrast to wild-type or control-transfected SW480 cells, the
DcR3-transfected cells produced high amounts of soluble DcR3
(fig 5A). The epithelial cell line HCT116 expresses the CD95
death receptor and is susceptible to CD95L-mediated cell death
(fig 5B and the supplement, part 13). However, when the cells
were co-treated with DcR3-containing supernatant from DcR3-
transfected cells, the CD95L-induced apoptosis was effectively
inhibited. In contrast, cell death induced by TRAIL, another
death ligand, was not inhibited by DcR3. To confirm the
protective effect of DcR3, we performed similar experiments
with human recombinant DcR3 (rhDcR3). CD95L-induced
cytotoxicity was completely abrogated by rhDcR3 protein even
at low concentrations (fig 5C). Again, the extent of TRAIL-
induced cell death was not altered by recombinant DcR3.
Decoy receptor 3 induces activation of nuclear factor kappa B
TNFa-induced activation of NF-kB-dependent pathways plays
an important role in inflammatory bowel disease.20 Since DcR3
expression can be induced by TNFa, we investigated whether
DcR3 itself promotes NF-kB activation. In fact, short-term
treatment of intestinal epithelial cells with DcR3 resulted in a
substantial degradation of IkBa which indicated NF-kB activa-
tion (fig 6). Since NF-kB signalling is also involved in the
transcriptional control of inflammation-associated adhesion
molecules such as ICAM-1,21 we examined a possible regulatory
role of DcR3 in ICAM-1 expression. We investigated the tissue
Inflammatory bowel disease
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distribution of ICAM-1 in inflamed small bowel specimens in
Crohn’s disease. ICAM-1 was detected in the endothelium of
small blood vessels, in mononuclear cells, and at the luminal
surface of enterocytes (fig 7). The increased expression of
ICAM-1 and DcR3 coincided at sites of acute inflammation.
CD95L-induced apoptosis of lamina propria T cells is blocked by
decoy receptor 3
Finally, we investigated the effects of increased DcR3 protein
levels on the site-specific immune effector cells in human
intestinal tissue. Lamina propria T cells were isolated from
freshly resected human bowel specimens. After CD3 stimula-
tion the T cells were incubated with CD95L in the presence or
absence of DcR3. The CD95L-dependent killing of T cells was
significantly more effective in CD3-stimulated T cells than in
the non-stimulated controls. However, in the presence of DcR3
the CD95L-mediated killing of T cells was almost completely
abolished (see the supplement, part 10).
DISCUSSION
In this study we first tried to identify genes that are
differentially regulated in the epithelial compartment of
intestinal tissues from patients suffering from Crohn’s disease.
After microdissecting fresh frozen small-intestinal mucosa
samples, the epithelial fraction was subjected to a global
expression analysis. These experiments resulted in the identifi-
cation of DcR3 as one of the genes which is significantly over-
expressed in the epithelial compartment in Crohn’s disease as
compared to non-inflamed normal controls.
The soluble DcR3 protein is a multi-functional modulator of
immune responses. The effects of DcR3 on the immune system
include inhibition of T cell chemotaxis, blockage of T cell
response to alloantigens, regulation of T cell interaction with
other immune competent cells, but also co-stimulation of
proliferation, lymphokine production, and cytotoxicity of
human T cells in the presence of T cell receptor (TCR)
ligation.22–25 Most of these effects are mediated by the
interaction of DcR3 with CD95L, LIGHT or TL1A, but
functions of DcR3 which are independent of ligand binding
have also been reported, such as increased monocyte adhesion.26
One study reported elevated expression levels of the decoy
receptors DcR1, DcR2 and DcR3 in lamina propria T cells in
chronic IBD.6 With respect to the epithelial compartment, an
increased expression of DcR3 has been demonstrated in
appendix epithelia from patients with acute appendicitis.27
However, the functional role of DcR3 in the epithelial
compartment in Crohn’s disease has not yet been addressed.
Our finding of upregulated epithelial DcR3 expression in
Crohn’s disease was confirmed by quantitative RT-PCR
analysis, immunoblot analysis of mucosal tissues and by
immunohistochemistry. Interestingly, the upregulation of
DcR3 in the intestinal epithelium in Crohn’s disease was
paralleled by a downregulation of two of the DcR3 ligands,
TL1A and CD95L (fig 1A and the supplement, part 12), which
indicates a predominance of CD95L- and TL1A-antagonising
signalling pathways in Crohn’s disease. A study by Kim et al27
demonstrated increased DcR3 expression in the epithelium in
acute appendicitis, indicating that upregulation of DcR3 is not
an exclusive phenomenon in Crohn’s disease. The authors
presented evidence that DcR3 expression in intestinal epithelial
cells is induced in response to lipopolysaccharide (LPS) involving
extracellular signal-related kinase (ERK)1/2-, cJun N-terminal
Figure 1 Decoy receptor 3 (DcR3) is upregulated in the epithelial cell
compartment in Crohn’s disease (CD). (A) Epithelial fractions of the
small intestine from patients with Crohn’s disease (actively inflamed
and inactive areas) and normal controls were obtained by laser
microdissection. Global gene expression profiles were generated by
gene chip analysis. The diagram depicts the ratios of the expression
levels of several genes in ileal tissue samples from patients with
Crohn’s disease versus control individuals (active inflammation, n = 3;
non-active inflammation, n = 3; controls, n = 3). (B) Upregulation of
DcR3 was confirmed by quantitative RT-PCR in microdissected human
ileal epithelium in an independent cohort of samples (active
inflammation, n = 8; non-active inflammation, n = 9; controls, n = 8).
Significantly higher expression of DcR3 occurred in active Crohn’s
disease vs control (p,0.001) and non-active Crohn’s disease vs
control (p,0.05). (C) Increased intestinal DcR3 protein expression in
Crohn’s disease. Protein lysates were generated from intestinal tissue
from patients with Crohn’s disease and control individuals. DcR3
migrates as a 33 kDa band in SDS–PAGE. Re-probing of the
membrane with an anti-b-actin antibody served as a loading and
transfer control. For a densitometric analysis of the immunoblot bands
see the supplement (part 14). IL8, interleukin 8; TL1A, TNF-like
molecule 1A.
Inflammatory bowel disease
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kinase (JNK)-, and NF-kB-dependent signalling pathways.27 28
Given the importance of LPS and innate bacterial–host
interactions for the immune status in the bowel mucosa, these
findings in accordance with our results suggest that DcR3 is
functionally involved in the pathogenesis of Crohn’s disease.
There are several possible consequences of elevated DcR3
production by enterocytes in Crohn’s disease. DcR3 may
protect enterocytes from CD95L-induced apoptotic cell death
which is possibly triggered by cytotoxic T cells at sites of acute
inflammation. Moreover, we present evidence that DcR3
induces the activation of NF-kB in intestinal epithelial cells
which may lead to the increased transcription of diverse pro-
survival genes. Thus, increased DcR3 production by enterocytes
could represent a protection mechanism of cells confronted
with a microenvironment of chronic inflammation. For
endothelial cells, it has been shown that DcR3 induces IkB
degradation and NF-kB DNA-binding activity.29 Moreover, we
now demonstrate that DcR3 expression in intestinal epithelial
cells is induced by TNFa (fig 4). In this context, it is of interest
that DcR3 was reported to be induced by TNFa in rheumatoid
synovial fibroblasts.30 Given the induction of DcR3 by TNFa
and the DcR3-mediated activation of NF-kB, DcR3 appears to
be functionally involved in the TNFa-dependent NF-kB regula-
tion in enterocytes. Since our respective experiments are cell
culture-based, future in vivo investigations are needed to dissect
the molecular mechanisms and possible redundancies in the
mutual relationship between DcR3, TNFa and NF-kB.
Figure 2 Immunohistochemical detection of decoy receptor 3 (DcR3) in active and non-active Crohn’s disease. The localisation of the DcR3 protein in
small-intestinal tissues from patients with Crohn’s disease or controls was examined by immunohistochemistry (active inflammation, n = 6; non-active
inflammation, n = 4; controls, n = 7). Weak immunoreactivity for DcR3 was observed in the non-inflamed intestinal mucosa (A). Prominent DcR3
expression was detected in the follicle-associated epithelium in Crohn’s disease, both in samples with non-active (C) and active (E) disease. Moreover,
epithelial cells exhibited strong DcR3 expression in the vicinity of ulcerative inflammation in patients with Crohn’s disease (G,I,K). The replacement of
the primary anti-DcR3 antibody with an immunoglobulin G1 isotype antibody served as a negative control (B,D,F,H,J,L). Original magnifications,620.
Figure 3 Serum concentrations of decoy receptor 3 (DcR3) in Crohn’s
disease. The concentrations of soluble DcR3 in the serum of patients
with Crohn’s disease (CD) was determined by ELISA. Serum samples of
healthy individuals (n = 27) served as a control. Compared with control
serum, DcR3 levels were significantly higher in patients with active CD
(n = 30) as well as non-active CD (n = 26).
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The activation of NF-kB-dependent pro-survival and prolif-
eration pathways plays an important role in many models of
tumorigenesis. Besides its immunoregulatory functions, DcR3 is
known to be over-expressed in many types of cancer, eg, lung
and gastrointestinal tract tumours and malignant gliomas.2 31–33
Since NF-kB activation has been implicated as an important
factor in the pathogenesis of colitis-associated colon carcino-
mas,34 DcR3 could very well play a role in the development of
IBD-associated colon cancer.
In light of the epithelial barrier dysfunction in IBD it is
intriguing that DcR3-dependent NF-kB activation has been
shown to upregulate cell–cell adhesion proteins such as ICAM-1
and vascular cell adhesion molecule-1 (VCAM-1), thereby
increasing the adhesion of monocytes to endothelial cells.29
The DcR3-induced increase in monocyte adhesion may be
mediated by the formation of cross-links between DcR3 and
proteoglycans.26 Immobilised DcR3 was also shown to induce
actin reorganisation, thereby enhancing the adhesion of mono-
cytes.35 We demonstrate that DcR3 and ICAM-1 are co-
expressed in the chronically inflamed mucosa at sites of acute
Figure 4 Transcriptional regulation of decoy receptor 3 (DcR3)
expression by tumour necrosis factor a (TNFa). HCT116 cells were
incubated with TNFa (10 ng/ml) or interleukin 1b (IL1b; 10 ng/ml) for
12 h or 24 h. Subsequently, RNA was extracted and subjected to
quantitative real-time polymerase chain reaction (RT-PCR) analysis of
DcR3 (A) or IL8 (B). Data are presented as mean with the standard
deviation (SD) (n = 3, t test, *p,0.05, **p,0.001, ***p,0.0001,
compared to controls; representative data from one of several
independent experiments with similar results are shown).
Figure 5 Decoy receptor 3 (DcR3) protects epithelial intestinal cells
from CD95L-induced cell death. (A) SW480 cells were stably transfected
with a human DcR3 expression plasmid, resulting in the production and
secretion of high amounts of DcR3 protein into the supernatant as
assessed by immunoblot analysis (left side). On the mRNA level, DcR3
was approximately 150-fold upregulated in DcR3-transfected SW480
cells (right side). (B) HCT116 cells were treated with CD95L for 24 h,
resulting in about 50% cell killing. The cells were almost completely
rescued from CD95L-induced apoptosis by addition of DcR3-containing
supernatant. In contrast, DcR3 did not protect the cells from TRAIL-
induced apoptosis. Data are presented as mean with the standard
deviation (SD) (n = 3, t test, *p,0.05, compared to controls).
(C) HCT116 cells were treated with CD95L as in (B). Human recombinant
DcR3 protein at low concentrations (10 ng/ml) completely abolished the
cytotoxic effects of CD95L. At higher concentrations, recombinant DcR3
promoted proliferation resulting in higher cell numbers compared to the
untreated control. TRAIL-induced cell death was not affected by
recombinant DcR3. Data are presented as mean with the SD (n = 3,
t test, *p,0.05, compared with controls).
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inflammation. Recent evidence suggests that ICAMs are
involved in leukocyte trafficking at endothelial or epithelial
surfaces and also play a role as target structures for viral and
bacterial pathogens at the intestinal mucosa.7 ICAM-1 is known
to be expressed at the follicle-associated epithelium (FAE),
suggesting a role in antigen sampling at such sites. Interestingly,
DcR3 showed a very similar expression pattern with the
presence of DcR3-positive cells in the FAE (fig 2). These
findings suggest that DcR3-mediated regulation of ICAM-1
might play a functional role in the invasion of pathogens and in
the epithelial/endothelial trafficking of leukocytes in Crohn’s
disease.
Besides its strong expression at sites of acute inflammation,
DcR3 is predominantly expressed at the FAE in the mucosa of
patients with Crohn’s disease. This finding could explain why
elevated DcR3 serum levels were observed not only in patients
with active Crohn’s disease, but also in patients with non-active
Crohn’s disease (fig 3). Future detailed studies are required to
address the question whether DcR3 serum levels or mucosal
biopsies could be used as a biological marker for early
manifestations of Crohn’s disease.
Finally, we present evidence that upregulated DcR3 expres-
sion in epithelial intestinal cells could also result in the blockage
of CD95L-dependent killing of lamina propria T cells (see the
supplement, part 10). Thus, locally elevated DcR3 tissue
concentrations could lead to the inhibition of CD95-mediated
activation-induced cell death of T cells, thereby contributing to
the accumulation of T lymphocytes in the chronically inflamed
mucosa.
Taken together, our results suggest that the soluble DcR3
protein is functionally relevant in the development and
progression of Crohn’s disease. Elevated DcR3 expression is
not specific for Crohn’s disease, since DcR3 is also involved in
other inflammatory and neoplastic conditions. This might limit
the possible use of DcR3 serum levels as a marker for Crohn’s
disease. However, our finding of increased DcR3 expression
even in non-inflamed gut areas in Crohn’s disease is important
and suggests that DcR3 is involved early in the disease process.
Increased ICAM-1 expression and the DcR3-dependent protec-
tion of lamina propria T cells from CD95L-induced cell death
might contribute to the perpetuation of inflammatory changes
in Crohn’s disease. The DcR3-mediated activation of NF-kB pro-
survival signalling pathways and the protection from CD95-
induced cell death may play a role in the transformation of
enterocytes to dysplastic cells and, finally, carcinoma cells.
Thus, DcR3 might represent an important molecular link
between inflammation and carcinogenesis in IBD. Future
Figure 6 Decoy receptor 3 (DcR3) induces the activation of nuclear
factor kappa B (NF-kB). (A) Activation of NF-kB was monitored by
immunoblot analysis of IkBa. HCT116 cells were incubated with
Dulbecco’s modified Eagle’s medium (DMEM) (C1, control 1), control
supernatant (C2, control 2), DcR3-containing supernatant, or human
recombinant tumour necrosis factor a (TNFa; 10 ng/ml) for 20 min or
60 min. (B) Densitometric analysis of the expression levels of IkBa vs b-
tubulin.
Figure 7 Co-expression of intracellular
adhesion molecule-1 (ICAM-1) and decoy
receptor 3 (DcR3) in inflammatory lesions
in Crohn’s disease. The expression of
ICAM-1 and DcR3 in small-intestinal
tissue from patients with Crohn’s disease
was examined on serial sections by using
immunohistochemistry. ICAM-1-specific
immunoreactivity was observed at the
luminal surface of epithelial cells (A), in
endothelial cells (C), and in mononuclear
cells. At sites of acute inflammation,
ICAM-1 and DcR3 (B,D) were frequently
co-expressed. Original magnifications,
640.
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investigations using rodent models with transgenic DcR3
expression36 will further characterise the functional relevance
of DcR3 in chronic intestinal inflammation.
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